Pediatric nintedanib trial in fibrosing interstitial lung disease

Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) comparing Nintedanib + standard of care, Placebo + standard of care and Open-label nintedanib extension (3 arms). Primary endpoints: Steady-state AUC and Treatment-emergent adverse events at week 24. Started Aug 2020; status: active, not recruiting.